Dr Reddy's Labs Q3 net beats f'casts on U.S. sales

19643 Investors following Dr Reddys Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Dr Reddy's Labs Q3 net beats f'casts on U.S. sales

Dr Reddy's , which makes generic molecules and pharmaceutical ingredients, said consolidated net profit rose to Rs 513 crore in October-December compared with Rs 273 crore a year earlier.

Post your opinion here

 

0

Tweet

Share on Tumblr

ALSO READ See latest News about Dr Reddys Labs See previous management interviews See what other Experts & Brokerages are saying about Dr Reddys Labs

Dr Reddy's Laboratories , India's No. 2 drugmaker by sales, reported a forecast-beating 88% jump in quarterly net profit as sales in its key U.S. market more than doubled.

Dr Reddy's , which makes generic molecules and pharmaceutical ingredients, said consolidated net profit rose to Rs 513 crore in October-December compared with Rs 273 crore a year earlier.

Income from sales and services grew 46% to Rs 2770 crore.

The launch of the generic version of Eli Lilly & Co's schizophrenia treatment drug Zyprexa in the U.S., in October, powered the surge in sales growth, Dr Reddy's said.

Dr Reddy's and Teva Pharmaceutical jointly enjoy a 180-day-exlcusivity to sell this USD 3.2-billion-a-year drug in the United States.

Analysts' expectations were for a net profit of Rs 399 crore on sales of Rs 2442 crore, Thomson Reuters StarMine data showed.

The drugmaker, which draws nearly half of its revenue from North America, also benefited from a sharp drop in the value of the rupee in the December quarter.

Its North American formulations sales more than doubled to Rs 1111 crore in the quarter when the Indian rupee fell more than 7% versus the U.S. dollar.

Shares in Dr Reddy's, valued at USD 5.63 billion, closed 2.4% higher at 1,670.75 rupees on Friday, in a firm Mumbai market <.BSESN>.

"The numbers are ahead of estimates simply because of the marketing exclusivity for generic Zyprexa in the U.S., while other regions are just in-line with expectations," Sushant Dalmia, analyst at Pinc Research, said.

"Going forward, the U.S. should continue to grow strong and would be a saviour... while other regions are facing (growth) troubles."

Indian drugmakers, which account for about a third of U.S. applications for approval to sell generics, are expected to add USD 2 billion to USD 2.5 billion in U.S. sales in the next five years, doubling their U.S. revenue, Morgan Stanley said in a report.

Drugs worth more than USD 140 billion are likely to go off patent in the next five years.

In the next few years, Dr Reddy's, along with its peers Ranbaxy Laboratories , Sun Pharmaceutical Industries and Lupin Ltd will compete for a host of big-ticket drugs losing patent protection.

These include Forest's Alzheimer's drug Namenda, anti-depressant Lexapro, and the blood clot drug Plavix, sold jointly by Bristol-Myers Squibb Co and Sanofi .

Dr Reddy's formulation sales in European and Russian markets rose 14% and 15%, respectively.

India sales grew 11% to Rs 333 crore while global income from manufacturing services and pharmaceutical ingredients grew 12% to Rs 555.99 crore.